Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, July to September 2023
Updated 6 November 2024
Applies to England
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-infographic-mrsa-mssa-and-gram-negative-bacteraemia-and-cdi-july-to-september-2023
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
P. aeruginosa bacteraemia
July to September 2022: 8 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
July to September 2023: 8 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella spp. bacteraemia
July to September 2022: 22 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
July to September 2023: 24 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
E. coli bacteraemia
July to September 2022: 73 out of every 100,000 persons developed an E. coli bacteraemia.
July to September 2023: 77 out of every 100,000 persons developed an E. coli bacteraemia.
S. aureus (MRSA and MSSA) bacteraemia and C. difficile infections
MRSA bacteraemia
July to September 2022: 1.4 out of every 100,000 persons developed an MRSA bacteraemia.
July to September 2023: 1.4 out of every 100,000 persons developed an MRSA bacteraemia.
MSSA bacteraemia
July to September 2022: 23 out of every 100,000 persons developed an MSSA bacteraemia.
July to September 2023: 23 out of every 100,000 persons developed an MSSA bacteraemia.
C. difficile infection
July to September 2022: 31 out of every 100,000 persons developed a C. difficile infection.
July to September 2023: 30 out of every 100,000 persons developed a C. difficile infection.